GI Oncology Now

The leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

ESMO24 GI Review: LEAP-012, TOPGEAR, and EMERALD

At the ESMO Congress 2024, Dr. Zev Wainberg reviews the latest data on gastrointestinal malignancies and notes that it is now unclear who should receive radiation before surgery. He discusses trials in gastric cancer, hepatocellular carcinoma, and pancreatic cancer.

Dr. Wainberg is optimistic about the future of the tricky endpoint that progression-free survival in hepatocellular carcinoma is known to be. He sees much compelling early-phase data for the drugs in the data presented.

Latest News

CHMP Recommends Tislelizumab for First-Line Therapy in Advanced Gastric and Esophageal Cancers

Brandon TwyfordGastric Cancer | October 22, 2024

Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.

FDA Approves VYLOY for Advanced, HER2-Negative Gastric and Gastroesophageal Junction Cancers

Laura LitwinGastric Cancer | October 18, 2024

FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.

Preoperative CRT and Pre/Periop CT Both Achieved Better Outcomes Than Surgery in AEG

Jordana JampelGastroesophageal Cancer | October 7, 2024

For postoperative morbidity and mortality, surgery alone had the highest probability rate.

The HIMALAYA Study: STRIDE for uHCC Shows Beneficial 5-Year OS Results

Lorenza Rimassa, MDUnresectable HCC | October 4, 2024

HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.

The POLAR Study: Pembrolizumab With Olaparib for Metastatic Pancreatic Cancer

Wungki Park, MD, MSPancreatic Cancer | September 27, 2024

Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.

ASP3082 in Patients With Solid Tumors and KRAS G12D Mutations

Wungki Park, MD, MSPancreatic Cancer | September 27, 2024

Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.

FGFR2 Fusions More Common in Early-Onset BTC Versus Average-Onset

Emily MenendezBile Duct Cancer | September 25, 2024

While biliary tract cancer is one of the fastest-growing types of early-onset cancers, little is known about its biology.

Trends in Genomic Alterations Among Demographic Groups With GISTs

Emily MenendezGIST | September 25, 2024

Little is known about the details of genomic differences and clinical implications between patients with GISTs.

FDA Grants Fast Track Designation for Fibroid-Targeting Inhibitor

Jordana JampelPancreatic Cancer | September 23, 2024

The FAK inhibitor narmafotinib targets solid tumors in pancreatic cancer.

POD1UM-303: Retifanlimab Plus Chemotherapy Improves PFS in Metastatic Squamous Cell Carcinoma of the Anal Canal

Brandon TwyfordGI Cancer | September 19, 2024

Retifanlimab plus chemotherapy showed improved PFS and response rates in locally recurrent or metastatic SCAC.

Roundtable Discussions

Oncology Brothers Event Coverage

Advancements in Oncology: GI Cancer

GI Oncology Now has exclusive coverage of Advancement in Oncology: Today’s Data for Tomorrow’s Practice, the first event co-hosted by The Oncology Brothers and Mashup Media. Review the breakthrough data on gastrointestinal cancers presented at the event and insights from esteemed experts that bridge the gap between research and practice for community oncologists.

Conference Coverage

ESMO 2024: GI Oncology Now

The latest news and research updates in GI cancer treatment from the ESMO Congress 2024

ASCO 2024: GI Oncology Now

The latest news and research updates in GI cancer treatment from the ASCO 2024 Annual Meeting

ASCO GI Symposium 2024

GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.

International Society of Gastrointestinal Oncology 2023 Annual Meeting

GI Oncology Now reviews education from ISGIO 2023, featuring the latest advances in the field of GI cancer research.

Expert Interviews

Benjamin Weinberg, MD, FACPEditor | Associate Professor of Medicine at Lombardi Comprehensive Cancer Center

Zev Wainberg, MD, MScEditor | Co-Director of Gastrointestinal Oncology at the University of California, Los Angeles